BeOne Medicines — CureCurrent

How to interpret these research links

Connected source records

The exact organization name BeOne Medicines appears in 13 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials13

Recruiting shown9

Roles2

SourceClinicalTrials.gov

Clinical trials

13 shown

A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)NCT07652736 · lead sponsor · 2026-06-05

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic DiseaseNCT07492641 · lead sponsor · 2026-05-22

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid TumorsNCT07222267 · lead sponsor · 2025-12-11

BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast CancerNCT06756932 · lead sponsor · 2025-02-04

A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsNCT06427941 · lead sponsor · 2024-07-23

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid TumorsNCT06120283 · lead sponsor · 2023-12-01

A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or AmplificationNCT06585488 · lead sponsor · 2024-12-13

A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung CancerNCT06685718 · lead sponsor · 2024-12-05

BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid TumorsNCT06253195 · lead sponsor · 2024-04-01

A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid TumorsNCT07623369 · collaborator · 2026-06-11

Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor TislelizumabNCT07510724 · collaborator · 2025-12-23

Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)NCT06598306 · collaborator · 2024-10-07

Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor BurdenNCT07715396 · collaborator · 2026-10-30

NOT_YET_RECRUITING

Sponsor roles

lead sponsor9

collaborator4

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.